Merck KGaA, Darmstadt, Germany a vibrant science and technology company, with over 64,000 employees in 66 countries. Our advanced solutions and innovative technology are life-changing, influencing the research to creating a better tomorrow. We offer one of the broadest portfolios in the industry for scientists and our presence extends well beyond the labs as our innovations touch individuals around the world. Before researchers can make scientific breakthroughs, they must have access to state-of-the-art tools, services, and expertise to perform experiments and engineer new products. This is where we begin our journey of collaboration with customers in academia, biomanufacturing and testing. For over 350 years, we have been at the forefront of technological and scientific advances, producing innovative products to demonstrate our dedication to drug discovery innovation.
Science and technology are at the heart of everything we do, driving innovations that enable us to contribute to a sustainable future and to tackle global challenges. We are committed to creating solutions that positively impact people and the environment. To this end, we are determined to make discoveries that change the landscape of entire industries and drive technological as well as scientific innovation to solve the most critical issues of today and tomorrow.
Our research teams develop innovative technologies for laboratory and life science applications in government and academic labs, the biopharmaceutical industry, the industrial sector and more. We use technology to solve new challenges, like seamlessly implementing single-use technology into lab workflow. We also bring fresh eyes to age-old challenges.
That’s where we come in. We offer one of the broadest portfolios in the industry for scientists. Researchers around the world rely on us to do their best science — from familiar experiments to novel approaches.
Our pharmaceutical and biotechnology customers look for expertise and products to improve every step of the manufacturing process, while startups look for holistic support to build and scale up theirs. To that end, we support our customers with both a team of technical experts and one of the most complete portfolios in the industry to enable safety and efficiency. M Lab™ Collaboration Centers offer vibrant spaces where our customers can explore ideas, learn new techniques, and work side-by-side with our scientists and engineers to solve critical process development challenges.
Are you looking to stay up-to-date with the latest developments in the pharmaceutical industry and enhance your knowledge of the chemical product portfolio? Look no further than Pharma Chemistry News, your exclusive source for the latest shared science, ongoing developments, and crucial information relevant to pharmaceutical chemists in Western Europe.
At Pharma Chemistry News, we strive to keep researchers and professionals informed and inspired, providing essential updates and breakthrough discoveries within this dynamic domain. Through our tailored webpage, we offer a wealth of resources to meet your needs and help you stay ahead in the world of pharmaceutical chemistry.
Join our community of experts and stay connected with us for the latest advancements in pharma chemistry. Whether you're seeking inspiration for your next breakthrough or need to stay on top of the latest industry trends, we've got you covered. With Pharma Chemistry News, you'll always be one step ahead in this ever-evolving field.
Examples of Innovative Solutions:
Expert-coded by chemists and engineered by computer scientists, learn about our Cloud-based Retrosynthesis Software Synthia™. What makes Synthia™ different from existing solutions? Reactions are coded by chemists and engineered by computer scientists. With Synthia™, you can:
- Simplify Route Design: quickly and efficiently scan hundreds of pathways to help you identify the best option according to your needs.
- Save Time and Reduce Costs: explore the most cost-effective routes to your target molecules with state-of-the-art visualization and filtering options.
- Meet Project Demands: easily customize search parameters to eliminate or promote reactions, reagents, or classes of molecules.
- Generate new ideas and IP: explore unique and innovative syntheses that may be unknown for building your desired molecule.
- Quickly Build a Shopping List: easily generate a list of commercially available starting materials for your synthesis.
- Your Data is Secure: benefit from ISO/IEC 27001 Information Security Certification to guarantee the confidentiality, integrity, and protection of your data.
Another cloud-based software with applications in drug discovery is AIDDISON™. AIDDISON™ brings together the power of artificial intelligence (AI), machine learning (ML), and computer-aided drug design (CADD) methods to act as a valuable toolkit for medicinal chemists. AIDDISON™ is a unified platform for efficient and effective ligand-based and structure-based drug design, integrating all the facets for virtual screening and supporting methods for lead discovery and lead optimization.
Several innovative technologies and products to aid researchers in the discovery and development of new drugs between targeted and therapeutic approaches. Some notable components of their portfolio are:
- Reagents and Probes for Target ID and Validation: Identifying and validating drug targets is a critical step in the drug discovery process. We provide a range of high-quality reagents and probes that assist researchers in this journey. These tools help researchers gain deeper insights into target biology and suitability for drug development.
- Micro Mapping Dexterity Kits: These kits provide researchers with the means to perform detailed mapping of protein interactions and epitopes. By understanding the precise interactions between proteins, researchers can design more targeted and effective drug candidates. This information is crucial for developing therapies that specifically target disease-related proteins.
- DNA Encoded Libraries - DYNA001 & DYNA002: we offer DNA-encoded libraries (DELs), a powerful tool for screening and identifying potential drug candidates. DELs are collections of small molecules that are linked to unique DNA barcodes, enabling researchers to simultaneously screen millions of compounds for their binding affinity to a specific target of interest. This technology accelerates the drug discovery process by quickly identifying hit compounds for further optimization.
- Targeted Protein Degradation Building Blocks: Targeted protein degradation is an emerging approach in drug discovery, and we offer building blocks and tools to support this novel strategy. These reagents facilitate the development of small molecules that can specifically target disease-causing proteins for degradation, offering new possibilities for challenging drug targets.
About Drug Discovery Innovation Programme 2023
Drug Discovery Innovation Programme is an invitation-only and one of the best platforms to learn the latest insights and develop lasting business relationships.
This year’s Drug Discovery Innovation Programme will highlight the challenges discovery pipelines have faced due to COVID-19 and will put a spotlight on thec adoption of technology to finding the solutions.
With over 100+ attendees, learn how modernization in R&D processes is fundamentally changing what the drug discovery research will look like in the next two to five years.
So, join us in 2023 for an in-person experience and 2-days of top-level strategic content and the current scientific insights, networking, and discussions from leading global pharmaceutical R&D executives.
Companies in attendance for 2023 will include Servier Pharmaceuticals, Monte Rosa Therapeutics, University of Oxford, WPD Pharmaceuticals, AISA Therapeutics, Anima Biotech, PDC*line Pharma, Eli Lillly and Company, Symphogen, IRB Barcelona, Axonis Therapeutics, Genentech, Arakis Therapeutics, Johnson & Johnson, Amgen, Revitale Pharma, Progenra Inc, CERo Therapeutics, Merck and much more.